Diligence memo · auto-generated · as of July 2, 2026
Lannett Co Inc
Lannett Co Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Lannett Co Inc operates in Pharmaceuticals, based in PHILADELPHIA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lannett Co Inc has raised $28M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $28M on 2021-04-22.
Most recent recorded round closed around 2021-04-22.
Valuation (modeled)modeled
Provath models Lannett Co Inc at approximately $691M (range $59M–$2.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.40× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era. Within the normal band (140% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5.2 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 72% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Evolus, Inc., HOOKIPA Pharma Inc., ESSA Pharma Inc., Pieris Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.